Evaluation of multidrug resistant phenotype by flow cytometry with monoclonal antibodies and functional tests.
Multidrug resistant (MDR) phenotype is characterized by a defect in drug accumulation caused by overexpression of a transmembrane glycoprotein, the P-glycoprotein (P-gp). MDR phenotype can be characterized either with monoclonal antibodies raised against P-gp or with functional tests, most often based on the incorporation of fluorescent compounds. In the present study, data obtained with the monoclonal antibodies C219, JSB1 and MRK16 are compared to those of functional tests performed by flow cytometry including uptake of daunorubicin (DNR), Rhodamine 123 (Rh 123) or Hoechst 33342. Sensitive and resistant cell lines K562S, K562R, KBA1 and KB31, derived either from a human chronic myeloid leukemia or from a human epithelial carcinoma, were used. In resistant cells, P-gp expression was revealed with either the monoclonal antibodies C219, JSB1 or MRK-16. The most specific results were obtained with MRK-16. With functional tests, no matter which dyes were used, the fluorescence was always stronger in sensitive than in resistant cells. However, with DNR and Hoechst 33342, an incorporation of these dyes was exhibited in resistant cells. This phenomenon was not observed with Rh 123, which makes it possible to distinguish clearly between sensitive and resistant cells and to detect as few as 1% of resistant cells. Because of its high sensitivity, the functional test involving incorporation of Rh 123 was successfully used in acute myeloid leukemia to detect multichemoresistant cells.
Lizard
G
G
Centre commun de cytométrie en flux, Inserm U80, hôpital E Herriot, Lyon, France.
Maynadié
M
M
Roignot
P
P
Lizard-Nacol
S
S
Poupon
M F
MF
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics*; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000964:Antimetabolites, Antineoplastic / Q000493:pharmacokinetics; D001562:Benzimidazoles / Q000493:pharmacokinetics; D003630:Daunorubicin / Q000493:pharmacokinetics; D018432:Drug Resistance, Multiple / Q000235:genetics*; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D005456:Fluorescent Dyes; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000276:immunology; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology; D010641:Phenotype; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology; D020112:Rhodamine 123; D012235:Rhodamines / Q000493:pharmacokinetics
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000911:Antibodies, Monoclonal; D000964:Antimetabolites, Antineoplastic; D001562:Benzimidazoles; D005456:Fluorescent Dyes; D012235:Rhodamines; D020112:Rhodamine 123; C017807:bisbenzimide ethoxide trihydrochloride; D003630:Daunorubicin